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Introduction: Agonistic autoantibodies (Aabs) against the angiotensin II receptor type 1 (AT1R) and the endothelin
receptor type A (ETAR) have been identified in patients with systemic sclerosis (SSc). In our present study, we
examined the expression of the AT1R and the ETAR in human immune cells and the pathological effects mediated
through these receptors by their corresponding Aabs.
Methods: Protein expression of AT1R and ETAR on peripheral blood mononuclear cells (PBMCs) from healthy
individuals and SSc patients was analyzed using flow cytometry, and mRNA expression of both receptors in PBMCs
from healthy donors was examined by real-time PCR. In addition, PBMCs from healthy donors were stimulated
in vitro with affinity-purified immunoglobulin G (IgG) fractions from SSc patients positive for AT1R and ETAR Aabs,
as well as with IgG from healthy donors serving as controls. Alterations in cell surface marker expression, cytokine
secretion and chemotactic motility were analyzed using flow cytometry, enzyme-linked immunosorbent assays and
chemotaxis assays, respectively. The results were correlated with the characteristics and clinical findings of the IgG
donors.
Results: Both AT1R and ETAR were expressed on PBMCs in humans. Protein expression of both receptors was
decreased in SSc patients compared with that of healthy donors and declined during the course of disease. IgG
fractions of SSc patients positive for AT1R and ETAR Aabs induced T-cell migration in an Aab level–dependent
manner. Moreover, IgG of SSc patients stimulated PBMCs to produce more interleukin 8 (IL-8) and chemokine
(C-C motif) ligand 18 (CCL18) than did the IgG of healthy donors. All effects were significantly reduced by selective
AT1R and ETAR antagonists. Statistical analysis revealed an association of SSc-IgG induced high IL-8 concentrations with
an early disease stage and of high CCL18 concentrations with lung fibrosis onset and vascular complications in the re-
spective IgG donors.
Conclusion: In our present study, we could demonstrate the expression of both AT1R and ETAR on human peripheral T
cells, B cells and monocytes. The decreased receptor expression in SSc patients, the inflammatory and profibrotic effects
upon Aab stimulation of PBMCs in vitro and the associations with clinical findings suggest a role for Aab-induced
activation of immune cells mediated by the AT1R and the ETAR in the pathogenesis or even the onset of the disease.* Correspondence: gabriela.riemekasten@charite.de
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Systemic sclerosis (SSc) is a severe rheumatic disease cha-
racterized by widespread fibrosis, vasculopathy and high
serum levels of agonistic autoantibodies (Aabs) [1,2]. Acti-
vation of the immune system has a crucial role in SSc
pathophysiology [3,4], and perivascular mononuclear cell
infiltrates are found before any histological evidence of
fibrosis [5]. These infiltrates are usually associated with
an early disease stage, and factors that are involved in
the progressive vasculopathy remain poorly defined [6].
Agonistic Aabs against the angiotensin II receptor type 1
(AT1R) and the endothelin receptor type A (ETAR) were
recently identified in the sera of SSc patients and are con-
sidered to contribute to the pathogenesis of the disease
[2]. As is typical of G protein–coupled receptors (GPCRs),
activation of AT1R and ETAR initiates several physio-
logical and pathophysiological processes [7-9]. Angioten-
sin II (Ang II), the major biologically active peptide of the
renin-angiotensin system, mediates its effect through the
AT1R and the angiotensin receptor type 2 (AT2R). Besides
its hemodynamic properties, Ang II can contribute to in-
flammation and fibrosis [7-9], primarily mediated through
the AT1R [10,11]. Endothelin is a strong vasoconstrictor.
Its known receptors are the ETAR and the endothelin re-
ceptor type B. The isoform endothelin 1 (ET-1), the most
abundant endothelin isoform in human plasma, shows the
highest affinity for the ETAR and is a potent mediator of
inflammation in the vasculature [12,13].
Inflammation belongs to the first events in the patho-
genesis of SSc, leading to vascular damage and fibrosis.
Several growth factors and cytokines involved in these
processes are altered in the serum and affected tissue of
SSc patients. Serum levels of Ang II and ET-1 are ele-
vated and have been shown to promote vascular injury
and fibrosis in SSc patients [14,15]. Thus, Ang II and
ET-1 appear to contribute to the pathogenesis of SSc.
Therefore, it is likely that Aabs, which act agonistically
through the AT1R and the ETAR, could drive the patho-
physiological process in SSc.
The expression of the AT1R in human peripheral
blood mononuclear cells (PBMCs) has been described
previously [8,16], but its function in immune cells re-
mains poorly understood. It has been demonstrated that
activation of the AT1R leads to a reduction in the acti-
vation threshold of murine T cells [17] and to a higher
chemotactic motility of human T cells, dendritic cells
and natural killer cells [8,18].
In our present study, we hypothesized that Aabs against
AT1R and ETAR could activate immune cells expressing
these receptors and thereby provide a link between the
adaptive and innate immune system. We analyzed the dif-
ferential expression of both receptors on human T cells, B
cells and monocytes from peripheral blood of healthy do-
nors and SSc patients. In addition, we investigated theeffects of the Aabs against these receptors on human
peripheral immune cells, the associations of the experi-
mental results with clinical findings and hence the




Rabbit polyclonal immunoglobulin G (IgG) anti-human
AT1R (N-10: sc-1173), rabbit polyclonal IgG anti-
human ETAR (H-60: sc-33535) and rabbit polyclonal
IgG isotype control (sc-3888) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Goat anti-
rabbit Alexa Fluor 430 (A-11064) was obtained from
Invitrogen (Carlsbad, CA, USA) as a secondary antibody.
Mouse IgG anti-human CD3 phycoerythrin (1273; clone
UCHT-1), mouse IgG anti-human CD19 cyanine 5 (Cy5)
(1624 clone BU12), mouse IgG anti-human CD14 fluo-
rescein isothiocyanate (FITC) (1353 clone TM1) and mouse
IgG anti-human CD14 Cy5 (1744 clone TM1) were ob-
tained from the German Rheumatism Research Center
(DRFZ; Berlin). Mouse IgG anti-human CD16 FITC
(555406) was obtained from BD Biosciences (Heidelberg,
Germany). Chemicals and reagents were purchased from
Sigma-Aldrich (Munich, Germany) unless stated otherwise.
Patients
Eighteen patients (mean age ± SD = 48.4 ± 11.3 years, 10
females and 8 males, 17 diffuse SSc and 1 limited SSc) and
fourteen healthy donors (mean age ± SD= 41.1 ± 15.3 years,
8 females and 6 males) were enrolled in our study of
AT1R and ETAR expression in PBMCs. IgG was isolated
from 32 patients (mean age = 57.9 ± 13.5 years, 24 females
and 9 males, 19 diffuse SSc and 14 limited SSc) and 10
healthy donors (mean age = 46.5 ± 6.3 years, 10 females
and 0 males). All patients had an established diagnosis of
SSc according to the SSc criteria of the American College
of Rheumatology [19]. The study was conducted in ac-
cordance with the Declaration of Helsinki and was
approved by the ethical committee of the University
Hospital Charité, Berlin. The patients gave us their written
informed consent to participate (EA1/042/09, EA1/013/05
and EA1/160/10).
The clinical subsets of diffuse SSc and limited SSc
were defined according to the classification system de-
scribed previously [20]. Clinical assessment was per-
formed using protocols standardized by the European
Scleroderma Trials and Research group [21].
Isolation of peripheral blood mononuclear cells and
immunoglobulin G
For PBMC isolation, venous blood was collected into he-
parinized tubes (BD Vacutainer Systems, Plymouth, UK).
PBMCs were prepared by centrifugation through a density
Günther et al. Arthritis Research & Therapy 2014, 16:R65 Page 3 of 14
http://arthritis-research.com/content/16/2/R65gradient on LSM1077 Lymphocyte Separation Medium
(PAA Laboratories, Pasching, Austria). To prepare cells for
RNA extraction, monocytes and lymphocytes were isolated
from the PBMCs of healthy donors by magnetic-activated
cell sorting according to the manufacturer’s instructions.
Monocytes were isolated by depletion of nonmonocytes
with the Monocyte Isolation Kit II, and T cells and B cells
were positively selected by means of anti-CD3 and anti-
CD19 magnetic beads, respectively (all obtained from
Miltenyi Biotec, Bergisch Gladbach, Germany). For che-
motaxis assays, T cells were isolated by depletion of non–
T cells by performing magnetic-activated cell sorting with
the Pan T Cell Kit (Miltenyi Biotec). The purity of the se-
lected populations was usually higher than 95% as assessed
by flow cytometry.
For IgG isolation, venous blood was collected into
ethylenediaminetetraacetic acid tubes (BD Vacutainer
Systems) and centrifuged to harvest the serum. IgG was
isolated by protein G sepharose chromatography in
20 mM phosphate buffer, pH 7.0. IgG was eluted with
0.1 M glycine HCl, pH 2.7, and pH was neutralized with
1 M Tris-HCl, pH 9.0. Eluted IgG was dialyzed against
phosphate-buffered saline (PBS). To determine protein
concentration, absorbance was measured at 280 nm (EMax
Endpoint ELISA Microplate Reader; Molecular Devices,
Sunnyvale, CA, USA). Anti-AT1R/ETAR titers were de-
tected in purified IgG as well as in serum by solid-phase
assay in cooperation with CellTrend GmbH (Luckenwalde,
Germany) using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (One Lambda, Canoga
Park, CA, USA) as previously described [2].
Flow cytometry
PBMCs were incubated in 1:10 diluted Flebogamma
(Instituto Grifols, Barcelona, Spain) to block nonspecific
binding sites. Afterward cells were incubated with the ap-
propriate concentrations of surface marker antibodies in a
PBS/bovine serum albumin (BSA) solution for 20 minutes
at 4°C. Prior to intracellular staining, cells were washed
with PBS, fixed with 4% formaldehyde and permeabilized
with 0.5% saponin. For receptor staining, cells were incu-
bated with the primary antibodies or the isotype control,
washed with PBS/BSA and incubated with the secondary
antibody, both for 45 minutes on ice. Cytometric mea-
surements were carried out using a LSR II flow cytometer
(BD Biosciences) and analyzed with FCS Express software
(DeNovo Software, Los Angeles, CA, USA) and FlowJo
software (TreeStar, Ashland, OR, USA).
RNA, cDNA and real-time PCR
mRNA was isolated by NucleoSpin RNA II (Macherey-
Nagel, Düren, Germany) and cDNA was generated by
Moloney murine leukemia virus reverse transcriptase
(Promega, Mannheim, Germany), each according to themanufacturer’s instructions. Real-time PCR reagents con-
tained 5 μl of cDNA, 0.25 mM deoxynucleotide triphos-
phates (Bioline, Luckenwalde, Germany), 12 μg/ml BSA, 1×
SYBR Green I (Molecular Probes, Darmstadt, Germany),
1 U of Immolase DNA Polymerase (Bioline), 500 mM Tris,
pH 8.8, 4 and 6 mM MgCl2, respectively, and 0.5 nmol/ml
primer mix (TIB MOLBIOL, Berlin, Germany). Reactions
were performed in an Mx3000P quantitative PCR thermal
cycler (Stratagene, Waldbronn, Germany). Primers were
designed using Primer Express 2.0 software (Applied Bio-
systems): AT1R (AGTR1) forward: 5′-TTC AGC CAG
CGT CAG TTT CA-3′, reverse: 5′-GGC-GGG-ACT-
TCA-TTG-GGT-3′; ETAR (EDNRA) forward: 5′-CAC
AGA GCT CAG CTT CCT GGT TA-3′, reverse: 5′-GTA
ATT TTA GTC TGC TGT GGG CAA TAG-3′; and
eukaryotic elongation factor 1 α1 (EF1A; housekeeping
gene EEF1A1) forward: 5′-GTT GAT ATG GTT CCT
GGC AAG C-3′, reverse: 5′-GCC AGC TCC AGC AGC
CTT C-3′.
T-cell culture and chemotaxis assays
Isolated T cells were cultured overnight at a concentration
of 1 to 2 million cells/ml in RPMI 1640 medium with
GlutaMAX (Gibco/Life Technologies, Grand Island, NY,
USA), 1% IgG-free fetal calf serum (FCS), 100 U/ml
penicillin and 100 µg/ml streptomycin (GE Healthcare Life
Sciences, Vienna, Austria) in a humidified atmosphere with
5% CO2 at 37°C. On the next day, cells were seeded at a
concentration of 1.0 to 1.3 million cells/ml in anti-CD3/
anti-CD28–coated well plates (10 and 5 μg/ml, respec-
tively, coated overnight at 4°C) and cultured for 3 days in
the presence of 10 μg/ml interleukin 2 (IL-2) under the
conditions described above. Cells were washed in PBS/BSA
and resuspended in assay medium (RPMI 1640 with 0.5%
BSA). Chemotaxis experiments were performed in trans-
well cell culture chambers with a polycarbonate membrane
of 5-μm pore size (Costar; Corning Life Sciences, Corning,
NY, USA). A total of 600,000 cells in 100 μl of the assay
medium was placed into the inserts. The inserts were po-
sitioned into individual wells containing 600 μl of assay
medium with or without 500 μg/ml IgG as indicated. The
AT1R antagonist valsartan (provided by Dominik N Müller,
Max-Delbrück-Centre for Molecular Medicine, Berlin,
Germany) or the ETAR antagonist sitaxsentan (provided
by Pfizer, New York, NY, USA) was added as indicated into
both the inserts and the corresponding wells. Valsartan
and sitaxsentan were used at concentrations of 10−5 M and
10−4 M, respectively. Appropriate concentrations of the an-
tagonists and IgG were determined in test experiments
using Ang II and ET-1. Plates were incubated for 2 hours
in a humidified atmosphere with 5% CO2 at 37°C. The
number of T cells that had migrated into the well was
quantified with a Neubauer hemocytometer (Marienfeld
Superior, Lauda-Königshofen, Germany).
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lated cells in transwell cell culture chambers with a
collagen-coated polycarbonate membrane of 3-μm pore
size (Costar; Corning Life Sciences). A total of 200,000
cells in 50 μl was placed into the inserts, and assays were
performed as described above. Migrated cells were quan-
tified using the adenosintriphosphate monitoring ATPlite
Luminescence Assay System (PerkinElmer, Waltham,
MA, USA) according to the manufacturer’s instructions.
Cell culture and stimulation of peripheral blood
mononuclear cells
Isolated PBMCs were cultured at a concentration of 1
to 2 million cells/ml in RPMI 1640 medium with
GlutaMAX, 1% IgG-free FCS, 100 U/ml penicillin and
100 μg/ml streptomycin (GE Healthcare Life Sciences)
in a humidified atmosphere with 5% CO2 at 37°C.
Valsartan or sitaxsentan was added to the cells at a concen-
tration of 10−5 and 6 × 10−5, respectively. After incubation
in 1:10 diluted Flebogamma (Instituto Grifols) to block
nonspecific binding sites, cells were treated with 1 mg/ml
IgG as indicated. Cell viability and appropriate concentra-
tions of the antagonists and IgG were determined in test
experiments. Cells and supernatants were collected after 8
and 20 hours, respectively, depending on the outcome
parameter, and then subjected to fluorescence-activated
cell-sorting analysis, real-time PCR or ELISA. To detach
adherent monocytes, they were washed with PBS and in-
cubated with Accutase (Innovative Cell Technologies, San
Diego, CA, USA) for 5 to 15 minutes at 37°C.
ELISA
Anti-AT1R and anti-ETAR Aabs were detected by using
a commercially available sandwich ELISA (One Lambda)
as described previously [2]. Because serum levels can dif-
fer from those of purified IgG, we tested Aab levels in
IgG fractions after purification. Anti-AT1R and anti-
ETAR Aab levels of IgG fractions from healthy donors
were usually below 10 arbitrary units, whereas those
from SSc patients ranged up to 40 arbitrary units.
Supernatants of treated PBMCs were collected after 8
and 20 hours, respectively, depending on the outcome
parameter. Cytokines and soluble proteins were analyzed
by performing sandwich ELISAs in a colorimetric detec-
tion system with tetramethylbenzidine, hydrogen perox-
ide and horseradish peroxidase. For the detection of IL-
8, renamed chemokine (CXC motif ) ligand 8 (CXCL8),
the anti-human IL-8 capture antibody H8A5 (Biolegend)
and the biotin-coupled detection antibody E8N1
(Biolegend) were used according to the manufacturer’s
instructions. To analyze the concentrations of chemokine
(C-C motif) ligand 18 (CCL18), transforming growth fac-
tor β1 (TGF-β1), soluble CD62 (sCD62) and soluble
CD14 (sCD14), duoset kits were used according to themanufacturer’s instructions (R&D Systems, Minneapolis,
MN, USA). Absorbance was measured in a microplate
reader at 450 nm and analyzed using SoftMax Pro version
5 software (Molecular Devices).
Statistical analysis
Data were evaluated statistically using GraphPad Prism
5 software (GraphPad Software, La Jolla, CA, USA).
Statistical significance was determined by the Mann-
Whitney U test, the Wilcoxon matched-pairs test and
Spearman’s correlation analysis. A value of P < 0.05 was
interpreted as statistically significant.Results
AT1R and ETAR are expressed in human PBMCs, and their
protein expression is decreased in SSc patients
Protein expression of AT1R and ETAR was measured
on T cells, B cells and monocytes by flow cytometry
(Figures 1A to 1D). In healthy donors, the density of
both receptors (represented by open boxes Figures 1A
and 1B) varied from a median fluorescence intensity
(MFI) of 1.3 to 1.8 relative to the isotype control in all an-
alyzed subsets and was lowest on B cells. The frequency of
AT1R-positive cells showed median values of 14% for
T cells, 12% for B cells and 73% for monocytes (repre-
sented by open boxes in Figure 1C). The frequency of
ETAR-positive cells showed median values of 10% for T
cells, 5% for B cells and 17% for monocytes (open boxes
Figure 1D). The frequency range of AT1R- and ETAR-
positive cells was large, especially in monocytes. Protein
expression data of healthy donors were confirmed by real-
time PCR to analyze mRNA expression of the receptors
in isolated T cells, B cells and monocytes (Figures 1E
and 1F).
Chronic receptor activation often results in down-
regulation. Therefore, the expression of the receptors
was studied on PBMCs of SSc patients in whom chronic
activation could be assumed because of the presence of
anti-AT1R/anti-ETAR Aabs in these patients. As shown
in Figure 1A, AT1R density was significantly decreased
on CD3+ T cells and CD14+ monocytes of SSc patients
(P < 0.01 and P < 0.05, respectively) compared with
those of healthy donors. In addition, the frequency of
AT1R-positive CD14+ monocytes (Figure 1C) was sig-
nificantly decreased (P < 0.05). The ETAR density and
frequency of ETAR-positive cells (Figures 1B and 1D)
were significantly decreased on the CD3+ T cells of
SSc patients compared with those of healthy donors
(P < 0.05).
Because of the high number of cells necessary to ana-
lyze mRNA expression of both receptors in different
PBMC subsets, we did not perform real-time PCR with
PBMCs of SSc patients.
Figure 1 Angiotensin II receptor type 1 and endothelin receptor type A are expressed in human peripheral blood mononuclear cells,
their protein expression is decreased in systemic sclerosis patients. Protein expression of both receptors in CD3+ T cells, CD19+ B cells and
CD14+ monocytes of systemic sclerosis (SSc) patients (n = 18) and healthy donors (n = 14) was measured by flow cytometry. (A) Density of
angiotensin II receptor type 1 (AT1R) and endothelin receptor type A (ETAR) (B) is represented by the median fluorescence intensity (MFI)
normalized to the isotype control. (C) Frequency of AT1R-positive cells and (D) ETAR-positive cells is represented by the percentage relative to
an isotype control. (E) AT1R mRNA (AGTR1) expression and (F) ETAR mRNA (ENDRA) expression in CD3+ T cells, CD19+ B cells and CD14+
monocytes of healthy donors (n = 3) was measured by real-time PCR and calculated using the 2−ΔCt method. Results are represented relative to
the housekeeping gene elongation factor 1 α1 (EF1A1). Statistical analysis was carried out by Mann–Whitney U test. Data are shown as box-and-
whisker plots (Tukey). *P < 0.05 and **P < 0.01.
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negatively with disease duration in SSc patients and age
in healthy individuals
In SSc patients, receptor expression on PBMCs may re-
flect patterns of the disease. When we compared receptor
expression with clinical data, we observed negative cor-
relations between the frequency of AT1R-positive CD14+
monocytes and the time since onset of Raynaud’s phe-
nomenon and first non-Raynaud’s symptom (Figures 2A
and 2B). Correlation analysis between the AT1R density
on CD14+ monocytes and the time from the onset ofRaynaud’s phenomenon and the first non-Raynaud’s
symptom revealed similar results (see Additional file 1).
No further associations were found between the recep-
tor expression data and clinical features such as disease
activity, lung function parameters or the presence of fur-
ther manifestations in SSc patients.
Statistical analysis of data from healthy individuals re-
vealed a negative correlation between protein expression
of both receptors and age, with statistical significance
for AT1R density on CD14+ monocytes and the fre-
quency of AT1R-positive CD14+ monocytes, and the
Figure 2 Angiotensin II receptor type 1 protein expression in monocytes of systemic sclerosis patients correlates negatively with
disease duration. Frequency of angiotensin II receptor type 1 (AT1R)-positive CD14+ monocytes shows a significant negative correlation with
(A) the time since onset of Raynaud’s phenomenon (patients with reported onset of Raynaud’s phenomenon; n = 16) and (B) the time since
onset of the first non-Raynaud’s symptom presenting the onset of the disease (patients with reported onset of the first non-Raynaud’s symptom;
n = 16). Statistical analysis was done by Spearman’s correlation. *P < 0.05.
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In patients, no age-related association was observed (see
Additional file 2).
Interestingly, in female healthy donors, both receptors
were expressed at a lower level in all analyzed PBMC pop-
ulations compared to those in male healthy donors
(see Additional file 3). Neither in patients nor in healthy
individuals AT1R expression results showed correlations
with those for the ETAR or with the respective Aab levels.
SSc-IgG-induced chemotaxis of T cells was reduced by
AT1R and ETAR antagonists and correlates positively with
Aab levels
As demonstrated above, PBMCs express AT1R and ETAR.
Therefore, activation of PBMCs through the AT1R and
the ETAR by agonistic Aabs must be supposed. To ad-
dress the hypothesis that lower frequencies of AT1R- and
ETAR-positive monocytes and T cells could result from
increased migration into the tissue due to Aab activation
in SSc patients, we performed chemotaxis assays. Ini-
tial migration experiments with freshly isolated PBMCs
through a collagen-coated membrane resulted in a signi-
ficantly higher number of PBMCs that migrated toward
IgG of SSc patients (SSc-IgG) compared with IgG of
healthy donors (HD-IgG), but the differences from the
medium control were low. Migration assays of isolated
monocytes provided no results, owing to the obviously
high activation status of the cells. Therefore, chemotaxis
assays were performed with isolated T cells. T cells mi-
grated toward the natural ligands Ang II and ET-1 and
toward SSc-IgG in a concentration-dependent manner
as studied in initial experiments. Migration was dose-
dependently inhibited by the AT1R antagonist valsartan
and the ETAR antagonist sitaxsentan (see Additional file 4).
As shown in Figure 3A, significantly more T cells mi-
grated toward SSc-IgG and HD-IgG than toward the
medium control. The numbers of T cells that migratedtoward SSc-IgG was higher compared with HD-IgG, but
this difference did not reach statistical significance. Che-
motaxis induced by SSc-IgG was significantly reduced
by the AT1R antagonist valsartan and the ETAR anta-
gonist sitaxsentan, but not the chemotaxis induced by
HD-IgG.
Strong correlations were found between the number
of T cells that migrated toward SSc-IgG and the anti-
AT1R and anti-ETAR Aab levels of the SSc-IgG fractions
(Figures 3B and 3C). In contrast, the number of T cells
that migrated toward HD-IgG did not correlate with
Aab levels (see Additional file 5).
No further associations were found between numbers
of migrated T cells and age, sex, disease form or other
clinical features of IgG donors.
PBMCs showed altered expression of cell surface markers
and secretion of cytokines when incubated with IgG from
SSc patients
IgG from SSc patients may induce inflammatory and
fibrotic conditions. Therefore, the differential expression
of activation markers, cytokines and soluble proteins was
analyzed after PBMCs of healthy donors were incubated
with either SSc IgG or HD IgG.
In monocytes, expression of CD14 on forward scatter/
side scatter–gated monocytes was significantly decreased
in SSc-IgG-stimulated samples (Figure 4A), whereas CD16
on CD14+ monocytes, but not on monocytes with dimi-
nished CD14 expression (CD14dim), was slightly increased
(Figure 4B). sCD14 in supernatant was significantly de-
creased, too (Figure 4C). Expression of human leukocyte
antigen major histocompatibility class II cell surface recep-
tor DR was not altered (see Additional file 6).
Incubation of PBMCs with SSc-IgG resulted in signifi-
cantly increased IL-8 concentrations in supernatants
when compared with incubation of PBMCs with
HD-IgG (Figure 4D). In addition, CCL18 was increased
Figure 3 Chemotaxis of T cells induced by immunoglobulin G from systemic sclerosis patients is reduced by receptor antagonists and
depends on autoantibody levels. (A) Number of T cells that migrated toward medium control (contr.), immunoglobulin G of healthy donors
(HD-IgG) and systemic sclerosis patients (SSc-IgG). Chemotaxis induced by SSc-IgG was significantly reduced by the angiotensin II receptor type 1
(AT1R) antagonist valsartan (Val) and the endothelin receptor type A (ETAR) antagonist sitaxsentan (Sit). Chemotaxis induced by HD-IgG was not
significantly reduced (n.s.). (B) Numbers of T cells that migrated toward SSc-IgG correlate with anti-AT1R Aab levels of the SSc-IgG fractions used.
(C) Numbers of T cells that migrated toward SSc-IgG correlate with anti-ETAR Aab levels of the SSc-IgG fractions used. Data are derived from five
independent migration assays done with a total of 13 SSc-IgG and 10 HD-IgG. Statistical analysis was done by Mann–Whitney U test (control vs.
HD-IgG, control vs. SSc-IgG and HD-IgG vs. SSc-IgG), Wilcoxon matched-pairs test (IgG vs. IgG with antagonist) and Spearman's correlation (B and
C). Mean +/- SEM are shown in (A). *P < 0.05.
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markable range up to more than 100-fold that of the
control (Figure 4E), reflecting the heterogeneity of re-
sponses induced by IgG from different SSc patients. The
SSc-IgG-induced TGF-β expression was only slightly in-
creased, and sCD62 was slightly decreased, compared
with the HD-IgG (see Additional file 6). The natural li-
gands Ang II and ET-1 did not modify the expression or
secretion of the tested proteins when applied alone.
SSc-IgG-induced IL-8 and CCL18 secretion was reduced by
AT1R and ETAR antagonists
IL-8 and CCL18 are strong mediators of inflammation
and fibrosis, respectively. Utilizing specific receptor an-
tagonists, we analyzed whether the observed IL-8 and
CCL18 responses of PBMCs induced by SSc-IgGsFigure 4 Immunoglobulin G of systemic sclerosis patients changed ex
secretion of cytokines. Peripheral blood mononuclear cells (PBMCs) from
either immunoglobulin (IgG) from healthy donors (HD-IgG) or systemic scle
(A) CD14 and (B) CD16 were measured on monocytes by flow cytometry,
The soluble protein CD14 (sCD14), as well as the cytokines (D) interleukin
measured in the supernatants by enzyme-linked immunosorbent assay. D
five HD-IgG and ten SSc-IgG normalized to the unstimulated control. Stati
box-and-whisker plots (Tukey). +P < 0.1, *P < 0.05 and **P < 0.01.(Figures 4D and 4E) were mediated through AT1R and/
or ETAR. Because of the high interassay variability due
to different cell donors that we had observed in the mi-
gration assays, we tested at first the IgG fractions of 26
SSc patients with the cells of one donor. IL-8 secretion
was decreased 21% by valsartan and 69.5% by sitaxsen-
tan (Figure 5A). CCL18 secretion was decreased 29% by
valsartan and 65% by sitaxsentan (Figure 5B). In a second
approach, we examined combined treatment with both
antagonists, but it did not improve the inhibiting effects
in the tested dosages (Figures 5C and 5D).
SSc-IgG-induced IL-8 concentrations correlate with clinical
features
We detected a wide range of IL-8 and CCL18 levels after
in vitro stimulation of PBMCs with SSc-IgG of severalpression of markers on peripheral blood mononuclear cells and
healthy donors (HD) were stimulated for 8 to 20 hours in vitro by
rosis (SSc) patients (SSc-IgG). Protein expression of cell surface markers
density is represented by the median fluorescence intensity (MFI). (C)
8 (IL-8) and (E) chemokine (C-C motif) ligand 18 (CCL18), were
ata derived from three independent experiments done with a total of
stical analysis was done by Mann–Whitney U test. Data are shown as
Figure 5 Receptor antagonists reduced interleukin 8 and chemokine (C-C motif) ligand 18 secretion, inhibiting effects are not additive.
(A) Interleukin 8 (IL-8) and (B) chemokine (C-C motif) ligand 18 (CCL18) concentrations in the supernatants of peripheral blood mononuclear cells (PBMCs)
from healthy donors after 8 hours of in vitro stimulation by immunoglobulin G of systemic sclerosis patients (SSc-IgG) after pretreatment with either
the angiotensin II receptor type 1 blocker valsartan (Val) or the endothelin receptor type A blocker sitaxsentan (Sit), measured by enzyme-linked
immunosorbent assay (ELISA) and normalized to the corresponding sample without any antagonist representing 100%. Data are derived from one experiment
done with 26 SSc-IgG. Simultaneous blocking with both antagonists did not improve the inhibiting effects: (C) IL-8 and (D) CCL18 concentrations in the
supernatants of PBMCs from three healthy donors after 8 hours of in vitro stimulation by SSc-IgG after pretreatment with valsartan (Val) or sitaxsentan (Sit)
or both (Val + Sit) measured by ELISA and normalized to the corresponding samples without any antagonist representing 100%. Data derived from three
independent experiments done with pooled IgG from thirteen SSc patients. Statistical analysis was done by Wilcoxon matched-pairs test. Medians (A and B)
and medians with range (C and D) are shown. ***P< 0.001.
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the capability of SSc-IgG to induce IL-8 and CCL18 may
correspond to clinical manifestations in the respective
IgG donors. Therefore, analyses were performed to cor-
relate the chemokine concentrations induced in vitro
with clinical data.
IL-8 concentrations in supernatants of PBMCs stim-
ulated with SSc-IgG revealed a negative correlation
with the time since onset of Raynaud’s phenomenon of
the respective IgG donor (Figure 6A). In line with this
observation, IgG from SSc patients in an early stage of
disease (0 to 6 years from the time of onset of the first
non-Raynaud’s symptom) caused significantly higher
IL-8 concentrations when compared with IgG levels of
patients in a late stage (more than 6 years since onset)
(Figure 6B). In addition, IL-8 concentrations revealed a
highly significant negative correlation with the time
since onset of pulmonary arterial hypertension (PAH)
(Figure 6C). A strong negative correlation was ob-
served between IL-8 concentrations in the superna-
tants and the diffusion capacity of the lung for carbon
monoxide (DLCO) measured in lung function tests
(Figure 6D). No associations were observed between IL-8
concentrations and age, sex, disease form, disease activity
or other clinical features, or the presence of Aabs against
centromere and Scl-70. Anti-AT1R and anti-ETAR Aab
levels of patients and of affinity-purified IgG fractions did
not correlate with IL-8 concentrations in supernatants or
with blocking effects of valsartan and sitaxsentan. Con-
centrations of IL-8 and CCL18 in supernatants did not
correlate with each other (see Additional file 7).SSc-IgG-induced CCL18 concentrations correlate with
clinical features
Correlation analysis of CCL18 concentrations in superna-
tants with clinical features of SSc-IgG donors revealed a
negative correlation with the time since lung fibrosis onset
(Figure 7A). In addition, IgGs of SSc patients with vascular
complications, including digital ulcers, PAH and renal cri-
sis, caused significantly higher CCL18 secretion than those
of patients without these complications (Figure 7B). No
correlations were identified between CCL18 concentrations
and time since onset of Raynaud’s phenomenon or onset
of SSc, and no associations were found between CCL18
concentrations and age, sex, disease activity or other clinical
features and Aab titers.
Discussion
Expression of AT1R and ETAR has been found in several
cell types, both receptors mediate the activation of various
pathways, depending on the function of the relevant tissue
[7-9,13-15,22]. In this study, we investigated the expres-
sion of the AT1R and the ETAR on human PBMCs of
healthy individuals and SSc patients, the functional conse-
quences of in vitro activation of these receptors on im-
mune cells by agonistic Aabs and the association of the
observed effects with important disease features.
AT1R and ETAR are expressed in PBMCs and
downregulated in SSc patients
In previous studies the expression of the AT1R on circu-
lating leukocytes has been described [8,16], but not the
expression of ETAR. As we have shown in the present
Figure 7 Chemokine (C-C motif) ligand 18 concentrations induced by immunoglobulin G of systemic sclerosis patients (SSc-IgG) in
supernatants correlate with clinical features of SSc-IgG donors. (A) Correlation of measured chemokine (C-C motif) ligand 18 (CCL18)
concentrations with the time since lung fibrosis onset (13 patients with reported lung fibrosis onset). (B) Association of measured CCL18 concentrations
in supernatants with the incidence of vascular complications (25 patients with reported vascular status). CCL18 concentrations were measured by
enzyme-linked immunosorbent assay. Statistical analyses were done by two-tailed Spearman's correlation (A) and Mann–Whitney U test (B). Data in (B)
are shown as box-and-whisker plot (Tukey’s test). *P< 0.05.
Figure 6 Interleukin 8 concentrations induced by immunoglobulin G of systemic sclerosis patients (SSc-IgG) in supernatants correlate
with clinical features of SSc-IgG donors. (A) Correlation of measured interleukin 8 (IL-8) concentrations with the time since Raynaud’s
phenomenon onset (26 patients with reported Raynaud’s phenomenon onset) and (B) classification into early and late stages of the disease
(0 to 6 years and >6 years since systemic sclerosis (SSc) onset, respectively) by means of the first non-Raynaud’s symptom onset (25 patients with
reported first non-Raynaud’s symptom onset). (C) Correlation of measured IL-8 concentrations with the time since onset of pulmonary arterial
hypertension (PAH; 10 patients with reported PAH onset) and (D) with the diffusion capacity of the lung for carbon monoxide (DLCO; 23 patients
with reported DLCO). IL-8 levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was done by two-tailed Spearman's
correlation (A, B and D) and by Mann–Whitney U test (B). Data in (B) are shown as box-and-whisker plot (Tukey). *P < 0.05, **P < 0.01.
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and monocytes (Figure 1). We studied protein expres-
sion of both receptors ex vivo by intracellular staining,
thereby avoiding alterations caused by steric impairment,
internalization and conformational changes of the recep-
tors induced by ligands or Aabs. Recently, nonspecific
binding of the anti-AT1R antibody sc-1173 has been de-
scribed [23]. However, we have confirmed the specificity
of the antibody by the anti-AT1R antibody ELISA we
performed to analyze AT1R Aabs in serum or purified
IgG (see Additional file 8). In addition, expression of
both receptors was confirmed on mRNA level by real-
time PCR, verifying the protein expression data, where
we also found the highest AT1R and ETAR expression
on monocytes and T cells.
Protein expression of both receptors was decreased on
PBMCs from SSc patients, especially on T cells and mono-
cytes (Figure 1). It is well-established that Ang II and ET-1,
as well as several growth factors, downregulate the expres-
sion of the AT1R and the ETAR, and that all of them are
increased in the serum of SSc patients [6,24-28]. Interna-
lization, degradation, desensitization and tolerance to ago-
nists are classical feedback mechanisms to respond to
short-term and long-term receptor activation [29,30]. We
suggest that, besides natural ligands and growth factors,
receptor-activating Aabs also diminish the expression of
the AT1R and the ETAR in PBMCs of SSc patients in the
long term. This notion is supported by our finding that
receptor expression on PBMCs of SSc patients appears to
decrease during the course of the disease (Figure 2). In line
with this, reduced AT1R expression has previously been
observed in vessels from granulomatous lesions of patients
with granulomatosis due to polyangiitis (formerly known
as Wegener’s granulomatosis), another vascular disease
characterized by inflammation, endothelial dysfunction
and Aabs that induce tissue damage [31]. Furthermore, de-
creased ETAR expression has been found in fibrotic lung
tissue and skin-derived fibroblasts from SSc patients
[24,28].
Other factors that can modulate receptor expression are
cytokines, hypoxia, nitric oxide, free radicals, estrogens
and progesterone [6,24-28]. Therefore, it is not surprising
that we found higher expression of AT1R and ETAR in
male donors than in female donors. Whether this could
explain the higher susceptibility of male SSc patients to
renal crisis or cardiomyopathy remains to be elucidated.
Role of AT1R- and ETAR- activating Aabs in SSc
In the present study we observed that SSc-IgG positive for
anti-AT1R and anti-ETAR Aabs induced T-cell migration
as well as IL-8 and CCL18 secretion from PBMCs in vitro.
These effects were significantly reduced by receptor anta-
gonists. The experimental results correlate with the cli-
nical data.The lower frequency of the AT1R and the ETAR on
PBMCs from SSc patients than that of healthy donors
may be due to increased migration of receptor-positive
cells. In this scenario, high levels of Ang II, ET-1 or Aabs
may trigger the invasion of immune cells into the sur-
rounding tissue. It has previously been reported that
Ang II is a potent chemoattractant for different immune
cells [8,18,32] and that ET-1 participates in mononuclear
cell infiltration by enhancing the expression of adhesion
molecules on fibroblasts [33]. In our present study,
PBMCs and isolated T cells migrated toward IgG in
a concentration-dependent manner (Additional file 4),
with a greater number of cells migrating toward SSc-IgG
than toward HD-IgG (Figure 3). The number of mi-
grated T cells correlated with the anti-AT1R and anti-
ETAR levels of the SSc-IgG fractions. In addition, T-cell
migration induced by SSc-IgG, but not that induced by
HD-IgG, was significantly reduced by AT1R and ETAR
blockers, confirming that the migration was mediated
mainly through the AT1R and the ETAR (Figure 3).
Functional antibodies against AT1R and ETAR have
been described in SSc as well as in other diseases
[2,34-45]. Both Aabs are biologically active and induced
direct receptor-mediated, extracellular signal–regulated
kinase 1/2 phosphorylation and increased profibrotic
TGF-β gene expression in the human microvascular endo-
thelial cell line 1 (HMEC-1), effects that could be dimin-
ished by the respective receptor antagonists. In addition,
the Aabs were predictive of mortality and showed strong
associations with fibrotic and vascular complications [2].
Thus, we hypothesized that these Aabs contribute to in-
flammatory and fibrotic conditions in SSc by activating
the receptors on immune cells similarly to Ang II and ET-
1. Ang II is involved in all stages of vascular inflammation
[9] by inducing several transcription factors and releasing
different cytokines and chemokines, such as IL-8
[34,46-50]. In addition, Ang II is involved in fibrosis,
whereby the AT1R acts as a profibrotic mediator and the
AT2R acts as an antifibrotic mediator [10]. Among the
transcription factors induced by Ang II, nuclear factor κB
(NF-κB) plays a crucial role in regulating several proin-
flammatory genes, including the IL-8 gene [47]. Ang
II–induced inflammation via NF-κB seems to involve ET-1
as well. ET-1 is a powerful mediator of inflammation in
the vasculature [13], and the addition of an ET-1 receptor
antagonist decreased NF-κB and inflammation in Ang II–
induced end-organ damage [51]. Thus, Ang II–induced
vascular inflammation might be amplified by cross talk
with the endothelin pathway.
In the present work, we used SSc-IgG fractions posi-
tive for anti-AT1R and anti-ETAR Aabs to analyze their
pathological effects on human monocytes and lympho-
cytes in vitro, because the innate and the adaptive im-
mune systems both have a role in the pathogenesis of
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sion on monocytes after incubation with SSc-IgG that was
not a result of a shedding effect, as shown by sCD14
ELISA results (Figure 3). In addition, there was slightly in-
creased CD16 expression, but not on the CD14dim popula-
tion. Therefore, we could not ascribe these surface marker
alterations to an activation or a known differentiation
type. Moreover, a desensitizing effect may have occurred.
This interesting effect needs to be studied in more detail
in the future.
TGF-β is a main profibrotic factor, produced by lym-
phocytes and monocytes among the PBMCs. On the basis
of our experience with endothelial cells (HMEC-1), we
expected SSc-IgG to trigger a strong TGF-β response [2].
Instead, we found that SSc-IgG-stimulated PBMCs se-
creted high levels of IL-8 and CCL18. IL-8 is a major in-
flammatory cytokine produced mainly by endothelial cells
and monocytes/macrophages. It acts as a chemoattractant
to neutrophils, T cells and monocytes. Thus, Aabs evoking
a strong IL-8 response can contribute to the perivascular
leukocyte infiltration, such as that observed in the early
stages of SSc [6,52]. In addition, IL-8 is able to activate
fibroblasts, thereby promoting fibrosis [53]. CCL18 is a
prototypic fibrotic cytokine released mainly by mono-
cytes/macrophages and dendritic cells. It acts as chemo-
attractant to lymphocytes and is constitutively present in
human plasma, contributing to the generation of primary
immune responses [54]. Enhanced CCL18 production has
been verified in several inflammatory skin and lung dis-
eases [55]. Monocytes of SSc patients and patients with
pulmonary fibrosis are known to express more CCL18
than those of healthy donors [56,57]. Both CCL18 and
Ang II are able to induce fibrotic effects via TGF-β-
independent signaling pathways [54,58-60]. Thus, Aab-
mediated CCL18 release can contribute to profibrotic
conditions independently of TGF-β.
Interestingly, although Ang II is able to induce the re-
lease of different cytokines such as IL-8 in other cell types
[46-50], no stimulatory effect was found without costi-
mulation when the effect of Ang II on T cells, has been
studied [7,17]. In line with this observation, and unlike
Aabs, we were unable to induce IL-8 and CCL18 expres-
sion in PBMCs by Ang II and ET-1 alone. Taken together,
the importance of costimuli for T-cell receptor activation
and cross talk between AT1R and ETAR could explain the
different effects of Aabs and natural ligands.
By pretreating cells with the pharmacological receptor
antagonists valsartan and sitaxsentan, we found a signifi-
cant reduction of SSc-IgG-induced IL-8 and CCL18 con-
centrations in the supernatants of PBMCs. This finding
supports our hypothesis that anti-AT1R and anti-ETAR
Aabs mediate inflammatory and profibrotic effects via an
activation of their respective receptor. Both antagonists
were able to inhibit IL-8 and CCL18 release, suggesting adirect association between either the release of the cyto-
kines or the effects of the two different Aabs. Correlation
analysis between IL-8 concentrations and the respective
CCL18 concentrations revealed a low negative regression
coefficient, implying that CCL18 does not account for
IL-8 release or vice versa. Moreover, IgGs from SSc pa-
tients induced high levels of either CCL18 or IL-8. Inhi-
bition of the AT1R by its respective antagonist, however,
reduced IL-8 and CCL18 secretion to a similar extent.
Also, the inhibition of the ETAR by its respective anta-
gonist reduced IL-8 and CCL18 secretion similarly. The
underlying mechanism of these observations is highly
speculative. One idea might be that the downstream sig-
naling events of both receptors have a crossing point
which confers the signal for IL-8 and CCL18 production.
Inhibition of the AT1R was less efficient than the inhi-
bition of ETAR. This might be a result of varying affinities
and avidities of the AT1R- and ETAR-activating Aabs,
respectively.
Aab-induced IL-8 and CCL18 concentrations correlate with
clinical findings of SSc-IgG donors
In our study, we analyzed the IL-8 and CCL18 secretion of
PBMCs after in vitro stimulation with SSc-IgGs positive for
anti-AT1R and anti-ETAR Aabs. Assuming that these anti-
bodies also play a pathological role in vivo, Aab-induced
IL-8 and CCL18 concentrations were correlated to clinical
findings in the donor patients. First, there was a significant
negative correlation between IL-8 concentrations with the
time since Raynaud’s phenomenon onset and PAH onset,
suggesting that the inflammatory activity of the Aabs is
high at the onset of certain disease manifestations and de-
creases during the course of disease. This observation is in
accord with the high IL-8 levels in the affected skin of pa-
tients in the early stages of SSc [61]. Changes in the avidity
and/or affinity of Aabs after disease onset have been de-
scribed previously [62] and remain to be studied further in
the future. Second, the negative correlation of IL-8 concen-
trations with the DLCO seems to be independent of the
course of the disease and may point out a direct association
between the capacity of the Aabs to induce IL-8 secretion
and the worsening of DLCO. This has been suggested by
previous work showing a significant negative correlation
between DLCO and IL-8 levels measured in bronchoalveo-
lar lavage fluid from SSc patients [63]. Third, high CCL18
concentrations were associated with vascular complications,
including digital ulcers, PAH and renal crisis, and corre-
lated negatively with the time since lung fibrosis onset, sug-
gesting that the profibrotic activity of the Aabs is higher at
the beginning of lung fibrosis. All of these complications re-
sult from fibrotic alterations, where CCL18 is known to be
highly involved [64,65]. Therefore, these findings support
the idea of an inflammatory and profibrotic activity of anti-
AT1R and anti-ETAR Aabs by IL-8 and CCL18 induction.
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The limitation of this study is the lack of purified Aabs
against AT1R and ETAR. Generation of functional
monoclonal antibodies against AT1R and ETAR, as well
as against other GPCRs, is a general problem unsolved
to date. Owing to the high volume of serum necessary
for specific autoantibody isolation, we isolated the whole
IgG fractions from sera of patients with that severe
disease and proved the specificity of AT1R- and ETAR-
mediated effects by the application of specific receptor
antagonists. Some of the Aab-induced IL-8 and CCL18
responses were not blockable, suggesting possible in-
volvement of antibodies directed toward other targets
involved in IL-8 and CCL18 pathways.
Conclusions
In our present study, we have demonstrated that not only
the previously identified AT1R but also the ETAR is
expressed on human peripheral T cells, B cells and mono-
cytes. Therefore, these immune cells are under direct con-
trol of the natural ligands Ang II and ET-1 as well as
of receptor-activating Aabs. In SSc patients, we found a
distinctly decreased receptor expression, probably reflect-
ing chronic activation. AT1R- and ETAR-mediated T-cell
migration and high IL-8 and CCL18 responses in immune
cells due to stimulation by receptor-activating Aabs
support our hypothesis that these Aabs contribute to an
inflammatory and profibrotic environment in the perivas-
cular tissue. The high inflammatory response induced by
Aabs of SSc patients in the early disease stages further
suggests a prominent role of Aabs in the initiation of SSc
as well as a possible benefit of receptor blockade in the
early stages of the disease.
Additional files
Additional file 1: Angiotensin II receptor type 1 protein expression
in monocytes of systemic sclerosis patients correlates negatively
with disease duration. Density of angiotensin II receptor type 1 (AT1R)
on CD14+ monocytes correlates negatively with (A) the time since onset
of Raynaud’s phenomenon (16 patients with reported onset of Raynaud’s
phenomenon) as a trend and (B) the time since onset of the first non-
Raynaud’s symptom presenting the onset of the disease (16 patients with
reported onset of the first non-Raynaud’s symptom). Statistical analysis
was done by Spearman's correlation. MFI, Median fluorescence intensity.
Additional file 2: Expression of both receptors correlates negatively
with age of healthy donors. (A) Angiotensin II receptor type 1 (AT1R)
density on CD14+ monocytes, (B) frequency of AT1R-positive CD14+
monocytes, (C) frequency of AT1R-positive CD19+ B cells and (D)
endothelin receptor type A (ETAR)-positive CD19+ B cells in healthy
donors (HD, upper panel) show a significant negative correlation with
age. In systemic sclerosis patients (SSc, lower panel), no age-related
association was observed. Statistical analysis was done by Spearman's
correlation. *P < 0.05 and **P < 0.01.
Additional file 3: Angiotensin II receptor type 1 and endothelin
receptor type A protein expression is lower on peripheral blood
mononuclear cells of healthy women than in those of healthy men.
Protein expression of both receptors in CD3+ T cells, CD19+ B cells andCD14+ monocytes of healthy women (n = 8) and healthy men (n = 6)
was measured by flow cytometry. (A) Density of the angiotensin II
receptor type 1 (AT1R) and (B) density of the endothelin receptor type A
(ETAR) is represented by the median fluorescence intensity normalized to
the isotype control. (C) Frequency of AT1R-positive cells and (D) frequency
of ETAR-positive cells is represented by the percentage relative to an isotype
control. Statistical analysis was done by Mann–Whitney U test. MFI, Median
fluorescence intensity. Data are shown as box-and-whisker plots (Tukey).
**P < 0.01.
Additional file 4: Angiotensin II, endothelin 1 and immunoglobulin
G of systemic sclerosis patients induced chemotaxis of T cells,
which was reduced with receptor antagonists. (A) Number of T cells
that migrated toward medium control, angiotensin II (Ang II) and
endothelin 1 (ET-1), as well as toward Ang II with different concentrations of
Ang II receptor type 1 (AT1R) antagonist valsartan and toward ET-1, with
different concentrations of endothelin receptor type A (ETAR) antagonist
sitaxsentan. (B) Number of T cells that migrated toward medium control
and toward immunoglobulin G of systemic sclerosis patients (SSc-IgG) at
different concentrations. (C) Number of T cells that migrated toward
medium control and toward 0.5 mg/ml SSc-IgG at different concentrations
of the AT1R antagonist valsartan and the ETAR antagonist sitaxsentan. Data
are summarized from four independent test experiments Mean +/- SEM are
shown.
Additional file 5: Chemotaxis of T cells induced by immunoglobulin
G of healthy donors is independent of autoantibody levels. (A)
Numbers of T cells that had migrated toward HD-IgG do not correlate
with levels of autoantibodies (Aab) against angiotensin II receptor type 1
(AT1R) of the immunoglobulin G fractions of healthy donors (HD-IgG)
used. (B) Numbers of T cells that migrated toward HD-IgG did not correlate
with levels of Aab against endothelin receptor type A (ETAR) of the HD-IgG
fractions used. Data derived from five independent migration assays done
with a total of ten HD-IgG. Statistical analysis was done by Spearman's
correlation.
Additional file 6: Immunoglobulin G from systemic sclerosis
patients did not change the expression and/or concentration of
human leukocyte antigen major histocompatibility class II cell
surface receptor DR (HLA-DR), transforming growth factor β1 and
soluble CD62L. Peripheral blood mononuclear cells from healthy
donors (HD) were stimulated for 8 hours in vitro by either
immunoglobulin G from HD (HD-IgG) or IgG from systemic sclerosis
patients (SSc-IgG). Protein expression of the cell-surface marker human
leukocyte antigen major histocompatibility class II cell surface receptor
DR (HLA-DR) (A) was measured by flow cytometry. Density is represented
by the median fluorescence intensity (MFI). The levels of the cytokine
transforming growth factor β1 (TGF-β1) (B) and the soluble protein CD62L
(sCD62L) (C) were measured in the supernatants by enzyme-linked
immunosorbent assay. Data are derived from three independent
experiments done with a total of five HD-IgG and ten SSc-IgG, normalized
to the unstimulated control. Statistical analysis was done by Mann-Whitney
U test. Data are shown as box-and-whisker plots (Tukey).
Additional file 7: No correlation exists between interleukin 8 and
chemokine (C-C motif) ligand 18 concentrations in supernatants
after stimulation by immunoglobulin G of systemic sclerosis
patients. Interleukin 8 (IL-8) and chemokine (C-C motif) ligand 18
(CCL18) concentrations in the supernatants of peripheral blood
mononuclear cells from healthy donors after 8 hours of in vitro
stimulation by immunoglobulin G of systemic sclerosis patients
(SSc-IgG) were measured by enzyme-linked immunosorbent assay.
Data from one experiment with 26 SSc-IgG. Statistical analysis was
done by Spearman's correlation.
Additional file 8: Specificity of the anti-Angiotensin II receptor
type-1 antibody sc-1173 (N10) from Santa Cruz Biotechnology
was tested using a commercially available sandwich enzyme-
linked immunosorbent assay (One Lambda). Plates were coated
with either membrane extracts from transfected Chinese hamster
ovary (CHO) cells overexpressing human angiotensin II receptor type 1
(AT1R+) or with membrane extracts from nontransfected CHO cells as
controls (AT1R−). Anti-AT1R antibody sc-1173 was applied in serial
dilution as indicated. OD, Optical density.
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systemic sclerosis patients; TGF-β1: Transforming growth factor β1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JG performed the experiments, data analyses and statistical analyses and
wrote the manuscript. AK performed the real-time PCRs. HH participated in
the migration assays and analyzed the Aab levels. JR participated in the
analysis of protein expression. MB designed the study. ES helped to write
the manuscript. MR, GB and DD contributed to the systematic review. GR
conceived of the study aims, participated in the study design and
contributed to the systematic review. All authors read and approved
the final manuscript.
Acknowledgements
We thank Kathrin Mattat, Tuula Geske, Heidi Hecker-Kia and Heidi Schliemann
for their excellent technical assistance. In addition, we thank Dominik N
Müller of the Max-Delbrück-Center for Molecular Medicine in Berlin, Germany,
for providing us the AT1R antagonist valsartan, and Pfizer Inc (New York, NY,
USA), for providing the ETAR antagonist sitaxsentan. This study was sup-
ported by the Charité University Hospital in Berlin, Germany; an Actelion
Endothelin Research Award; a Zentrales Innovationsprogramm für den
Mittelstand (ZIM) grant from the Ministry of Industry of Germany; and a
European League Against Rheumatism ARTICULUM fellowship. This work is
part of the doctoral thesis of JG.
Author details
1Department of Rheumatology and Clinical Immunology, University Hospital
Charité, Charitéplatz 1, 10117 Berlin, Germany. 2German Rheumatism
Research Center (DRFZ), Leibniz Institute, Charitéplatz 1, 10117 Berlin,
Germany. 3CellTrend GmbH, Im Biotechnologiepark, 14943 Luckenwalde,
Germany. 4Department of Rheumatology and Clinical Immunology,
University Hospital Split, Soltanska 1, HR-21000 Split, Croatia. 5Department of
Nephrology, Transplantology and Intensive Care, University Hospital Charité,
Augustenburger Platz 1, 13353 Berlin, Germany.
Received: 21 March 2013 Accepted: 22 January 2014
Published: 11 March 2014
References
1. Sakkas LI, Chikanza IC, Platsoucas CD: Mechanisms of disease: the role of
immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract
Rheumatol 2006, 2:679–685.
2. Riemekasten G, Philippe A, Näther M, Slowinski T, Müller DN, Heidecke H,
Matucci-Cerinic M, Czirják L, Lukitsch I, Becker M, Kill A, van Laar JM, Catar R,
Luft FC, Burmester GR, Hegner B, Dragun D: Involvement of functional
autoantibodies against vascular receptors in systemic sclerosis.
Ann Rheum Dis 2011, 70:530–536.
3. Sakkas LI, Platsoucas CD: Is systemic sclerosis an antigen-driven T cell
disease? Arthritis Rheum 2004, 50:1721–1733.
4. Abraham DJ, Varga J: Scleroderma: from cell and molecular mechanisms
to disease models. Trends Immunol 2005, 26:587–595.
5. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P: Sequential
dermal microvascular and perivascular changes in the development of
scleroderma. J Pathol 1992, 166:255–263.
6. Trojanowska M: Cellular and molecular aspects of vascular dysfunction in
systemic sclerosis. Nat Rev Rheumatol 2010, 6:453–460.7. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS,
Ruiz P, Smithies O, Coffman TM: Angiotensin II regulates cellular immune
responses through a calcineurin-dependent pathway. J Clin Invest 1999,
104:1693–1701.
8. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter
CB, Milford E, Abdi R: Human T and natural killer cells possess a
functional renin-angiotensin system: further mechanisms of angiotensin
II-induced inflammation. J Am Soc Nephrol 2007, 18:1093–1102.
9. Marchesi C, Paradis P, Schiffrin EL: Role of the renin-angiotensin system in
vascular inflammation. Trends Pharmacol Sci 2008, 29:367–374.
10. Brassard P, Amiri F, Schiffrin EL: Combined angiotensin II type 1 and type
2 receptor blockade on vascular remodeling and matrix
metalloproteinases in resistance arteries. Hypertension 2005, 46:598–606.
11. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J:
Inflammation and angiotensin II. Int J Biochem Cell Biol 2003, 35:881–900.
12. Frommer KW, Müller-Ladner U: Expression and function of ETA and ETB
receptors in SSc. Rheumatology (Oxford) 2008, 47:v27–v28.
13. Schiffrin EL: Vascular endothelin in hypertension. Vascul Pharmacol 2005,
43:19–29.
14. Bellisai F, Morozzi G, Scaccia F, Chellini F, Simpatico A, Pecetti G, Galeazzi M:
Evaluation of the effect of bosentan treatment on proinflammatory
cytokine serum levels in patients affected by systemic sclerosis.
Int J Immunopathol Pharmacol 2011, 24:261–264.
15. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M,
Kamatani N: Angiotensin II in the lesional skin of systemic sclerosis patients
contributes to tissue fibrosis via angiotensin II type 1 receptors.
Arthritis Rheum 2004, 50:216–226.
16. Rasini E, Cosentino M, Marino F, Legnaro M, Ferrari M, Guasti L, Venco A,
Lecchini S: Angiotensin II type 1 receptor expression on human
leukocyte subsets: a flow cytometric and RT-PCR study. Regul Pept 2006,
134:69–74.
17. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C,
Harrison DG: Regulation of T-cell function by endogenously produced
angiotensin II. Am J Physiol Regul Integr Comp Physiol 2009,
296:R208–R216.
18. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE: Angiotensin II
induces migration and Pyk2/paxillin phosphorylation of human
monocytes. Hypertension 2001, 37:587–593.
19. Subcommittee for scleroderma criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria Committee: Preliminary
criteria for the classification of systemic sclerosis (scleroderma).
Arthritis Rheum 1980, 23:581–590.
20. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr,
Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification,
subsets and pathogenesis. J Rheumatol 1988, 15:202–205.
21. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O,
Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M: Clinical risk
assessment of organ manifestations in systemic sclerosis: a report from
the EULAR Scleroderma Trials and Research group database. Ann Rheum
Dis 2007, 66:754–763.
22. Mayes MD, Trojanowska M: Genetic factors in systemic sclerosis.
Arthritis Res Ther 2007, 9:S5.
23. Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM:
Lack of specificity of commercial antibodies leads to misidentification of
angiotensin type 1 receptor protein. Hypertension 2013, 61:253–258.
24. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P,
Xu SW, du Bois RM, Black CM: Increased levels of endothelin-1 and
differential endothelin type A and B receptor expression in scleroderma-
associated fibrotic lung disease. Am J Pathol 1997, 151:831–841.
25. Nickenig G: Central role of the AT1-receptor in atherosclerosis. J Hum
Hypertens 2002, 16:S26–S33.
26. Trojanowska M, Varga J: Molecular pathways as novel therapeutic targets
in systemic sclerosis. Curr Opin Rheumatol 2007, 19:568–573.
27. Ouali R, Berthelon MC, Bégeot M, Saez JM: Angiotensin II receptor
subtypes AT1 and AT2 are down-regulated by angiotensin II through
AT1 receptor by different mechanisms. Endocrinology 1997,
138:725–733.
28. Mayes MD: Endothelin and endothelin receptor antagonists in systemic
rheumatic disease. Arthritis Rheum 2003, 48:1190–1199.
29. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S,
Koch T, Evans CJ, Christie MJ: Regulation of μ-opioid receptors:
Günther et al. Arthritis Research & Therapy 2014, 16:R65 Page 14 of 14
http://arthritis-research.com/content/16/2/R65desensitization, phosphorylation, internalization, and tolerance.
Pharmacol Rev 2013, 65:223–254.
30. Rajagopal S, Rajagopal K, Lefkowitz RJ: Teaching old receptors new tricks:
biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010,
9:373–386.
31. Dimitrijevic I, Rissler P, Luts L, Edvinsson L: Reduced expression of
angiotensin II and angiotensin receptor type 1 and type 2 in resistance
arteries from nasal lesions in granulomatosis with polyangiitis
(Wegener’s granulomatosis). Scand J Rheumatol 2011, 40:448–452.
32. Silva-Filho JL, Souza MC, Henriques M, Morrot A, Savino W, Nunes MP, Caruso-
Neves C, Pinheiro AA: AT1 receptor-mediated angiotensin II activation and
chemotaxis of T lymphocytes. Mol Immunol 2011, 48:1835–1843.
33. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM: Endothelin-1
regulation of intercellular adhesion molecule-1 expression in normal and
sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998, 31:S545–S547.
34. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R,
Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann
C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type
1–receptor activating antibodies in renal-allograft rejection. N Engl J Med
2005, 352:558–569.
35. Okruhlicova L, Morwinski R, Schulze W, Bartel S, Weismann P, Tribulova N,
Wallukat G: Autoantibodies against G-protein-coupled receptors
modulate heart mast cells. Cell Mol Immunol 2007, 4:127–133.
36. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E,
Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with
preeclampsia develop agonistic autoantibodies against the angiotensin
AT1 receptor. J Clin Invest 1999, 103:945–952.
37. Xia Y, Wen H, Bobst S, Day MC, Kellems RE: Maternal autoantibodies from
preeclamptic patients activate angiotensin receptors on human
trophoblast cells. J Soc Gynecol Investig 2003, 10:82–93.
38. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A,
Kellems RE, Xia Y: Autoantibody from women with preeclampsia induces
soluble Fms-like tyrosine kinase-1 production via angiotensin type 1
receptor and calcineurin/nuclear factor of activated T-cells signaling.
Hypertension 2008, 51:1010–1019.
39. Xia Y, Kellems RE: Is preeclampsia an autoimmune disease? Clin Immunol
2009, 133:1–12.
40. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH,
Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC,
Müller DN: Agonistic autoantibodies to the AT1 receptor in a transgenic
rat model of preeclampsia. Hypertension 2005, 45:742–746.
41. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A,
Gulba DC, Mackman N, Haller H, Luft FC: AT(1) receptor agonistic
antibodies from preeclamptic patients cause vascular cells to express
tissue factor. Circulation 2000, 101:2382–2387.
42. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK,
Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J,
Luft FC: AT1 receptor agonistic antibodies from preeclamptic patients
stimulate NADPH oxidase. Circulation 2003, 107:1632–1639.
43. Bobst SM, Day MC, Gilstrap LC 3rd, Xia Y, Kellems RE: Maternal autoantibodies
from preeclamptic patients activate angiotensin receptors on human
mesangial cells and induce interleukin-6 and plasminogen activator
inhibitor-1 secretion. Am J Hypertens 2005, 18:330–336.
44. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H:
Angiotensin II type 1 receptor agonistic antibodies reflect fundamental
alterations in the uteroplacental vasculature. Hypertension 2005,
46:1275–1279.
45. Hiemann NE, Meyer R, Wellnhofer E, Schoenemann C, Heidecke H,
Lachmann N, Hetzer R, Dragun D: Non-HLA antibodies targeting vascular
receptors enhance alloimmune response and microvasculopathy after
heart transplantation. Transplantation 2012, 94:919–924.
46. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerdá-Nicolás M, Proudfoot AEI,
Stahl RAK, Issekutz AC, Cortijo J, Morcillo EJ, Jose PJ, Sanz MJ: Angiotensin
II-induced mononuclear leukocyte interactions with arteriolar and venular
endothelium are mediated by the release of different CC chemokines.
J Immunol 2006, 176:5577–5586.
47. Savoia C, Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol
Hypertens 2006, 15:152–158.
48. Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS: Angiotensin II
induces gene transcription through cell-type-dependent effects on thenuclear factor-κB (NF-κB) transcription factor. Mol Cell Biochem 2000,
212:155–169.
49. Nabah YN, Mateo T, Estellés R, Mata M, Zagorski J, Sarau H, Cortijo J,
Morcillo EJ, Jose PJ, Sanz MJ: Angiotensin II induces neutrophil
accumulation in vivo through generation and release of CXC
chemokines. Circulation 2004, 110:3581–3586.
50. Schmidt-Ott KM, Kagiyama S, Phillips MI: The multiple actions of
angiotensin II in atherosclerosis. Regul Pept 2000, 93:65–77.
51. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, Breu V,
Löffler BM, Ganten D, Schneider W, Haller H, Luft FC: Effect of bosentan on
NF-κB, inflammation, and tissue factor in angiotensin II-induced end-
organ damage. Hypertension 2000, 36:282–290.
52. Varga J, Abraham D: Systemic sclerosis: a prototypic multisystem fibrotic
disorder. J Clin Invest 2007, 117:557–567.
53. De Palma R, D’Aiuto E, Vettori S, Cuoppolo P, Abbate G, Valentini G:
Peripheral T cells from patients with early systemic sclerosis kill
autologous fibroblasts in co-culture: Is T-cell response aimed to play a
protective role? Rheumatology (Oxford) 2010, 49:1257–1266.
54. Prasse A, Pechkovsky DV, Toews GB, Schäfer M, Eggeling S, Ludwig C,
Germann M, Kollert F, Zissel G, Müller-Quernheim J: CCL18 as an indicator
of pulmonary fibrotic activity in idiopathic interstitial pneumonias and
systemic sclerosis. Arthritis Rheum 2007, 56:1685–1693.
55. Schutyser E, Richmond A, Van Damme J: Involvement of CC chemokine
ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol
2005, 78:14–26.
56. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA,
Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL:
Circulating monocytes from systemic sclerosis patients with interstitial lung
disease show an enhanced profibrotic phenotype. Lab Invest 2010,
90:812–823.
57. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T,
Vollmer E, Müller-Quernheim J, Zissel G: A vicious circle of alveolar
macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18.
Am J Respir Crit Care Med 2006, 173:781–792.
58. Luzina IG, Tsymbalyuk N, Choi J, Hasday JD, Atamas SP: CCL18-stimulated
upregulation of collagen production in lung fibroblasts requires Sp1
signaling and basal Smad3 activity. J Cell Physiol 2006, 206:221–228.
59. Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, Ruiz-
Ortega M: Angiotensin II activates the Smad pathway in vascular smooth
muscle cells by a transforming growth factor-β-independent mechanism.
Circulation 2005, 111:2509–2517.
60. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W,
Bottinger EP, Lan HY: Essential role of Smad3 in angiotensin II-induced
vascular fibrosis. Circ Res 2006, 98:1032–1039.
61. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA,
Strieter RM, Kunkel SL, Massa MC, Barr WG, Jimenez SA: In situ expression of
cytokines and cellular adhesion molecules in the skin of patients with
systemic sclerosis: their role in early and late disease. Pathobiology 1993,
61:239–246.
62. Suwannalai P, van de Stadt LA, Radner H, Steiner G, El-Gabalawy HS, Zijde
CM, van Tol MJ, van Schaardenburg D, Huizinga TW, Toes RE, Rouw LA:
Avidity maturation of anti-citrullinated protein antibodies in rheumatoid
arthritis. Arthritis Rheum 2012, 64:1323–1328.
63. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG,
Becker MO, Huscher D, Burmester GR, Riemekasten G: Bronchoalveoloar
lavage fluid cytokines and chemokines as markers and predictors for the
outcome of interstitial lung disease in systemic sclerosis patients.
Arthritis Res Ther 2009, 11:R111.
64. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S: Serum
pulmonary and activation-regulated chemokine/CCL18 levels in patients
with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Arthritis Rheum 2005, 52:2889–2896.
65. Prasse A, Müller-Quernheim J: Non-invasive biomarkers in pulmonary
fibrosis. Respirology 2009, 14:788–795.
doi:10.1186/ar4503
Cite this article as: Günther et al.: Angiotensin receptor type 1 and
endothelin receptor type A on immune cells mediate migration and the
expression of IL-8 and CCL18 when stimulated by autoantibodies from
systemic sclerosis patients. Arthritis Research & Therapy 2014 16:R65.
